香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確 性或完整性亦不發表任何聲明，並表明概不就因本公告全部或任何部分內容而產生或因依賴 該等內容而引致的任何損失承擔任何責任。 北 京 市 春 立 正 達 醫 療 器 械 股 份 有 限 公 司 Beijing Chunlizhengda Medical Instruments Co., Ltd.* * 僅供識別 代表董事會 北京市春立正達醫療器械股份有限公司 董事長 史文玲 中國，北京，2025年8月19日 截至本公告日期，執行董事為史文玲女士、史春寶先生、岳術俊女士及解鳳寶先生；非執行 董事為王鑫先生；及獨立非執行董事為徐泓女士、黃德盛先生及翁杰先生。 （ 於 中 華 人 民 共 和 國 註 冊 成 立 的 股 份 有 限 公 司 ） （股 份 代 號：1858） 董事會會議通告 北京市春立正達醫療器械股份有限公司（「本公司」）之董事會（「董事會」）謹此 宣佈將於2025年8月29日（星期五）舉行董事會會議，藉以（其中包括）批准本公 司及其附屬公司截至2025年6月30日止六個月之中期業績公佈及考慮派付中期 股息（如有）。 ...

Group 1 - The core viewpoint of the news is that Spring Medical has shown significant stock performance, with an 88.85% increase in stock price year-to-date, despite a recent decline of 3.99% over the last five trading days [1] - As of August 19, the stock price of Spring Medical is 24.08 CNY per share, with a market capitalization of 9.236 billion CNY and a trading volume of 13.42 million CNY [1] - The company primarily engages in the research, production, and sales of orthopedic medical devices, focusing on joint prosthetics and spinal implants, with 99.92% of its revenue coming from medical device products [1][2] Group 2 - As of March 31, the company reported a revenue of 230 million CNY for Q1 2025, representing a year-on-year growth of 3.60%, and a net profit of 58.07 million CNY, which is a 5.20% increase compared to the previous year [2] - The company has distributed a total of 359 million CNY in dividends since its A-share listing, with 309 million CNY distributed over the past three years [3] - The number of shareholders increased by 7.48% to 7,182 as of March 31, while the average number of circulating shares per person decreased by 6.99% to 11,063 shares [2]

Core Viewpoint - The company is actively positioning itself in the cutting-edge field of medical device technology, focusing on innovative surgical robots for joint procedures [1] Group 1 - The company has successfully obtained registration certificates for its hip joint surgical robot, knee joint surgical robot, and unicompartmental surgical robot [1] - The company aims to continuously integrate innovative technologies to drive product iteration and performance breakthroughs [1]

Group 1 - The Shanghai Composite Index rose by 0.85% to close at 3728.03 points, while the Hang Seng Index fell by 0.37% to close at 25176.85 points [1] - Chuangli Medical's A/H share premium reached 52.01%, ranking 67th among A/H shares [1] - On the closing day, Chuangli Medical's A-shares were priced at 23.58 yuan, down 0.8%, and H-shares at 16.9 HKD, up 0.18% [1] Group 2 - Chuangli Medical, established in 1998, focuses on the continuous development and research of high-end medical devices, covering a full range of orthopedic products including joint, spine, sports medicine, and trauma categories [1] - The company has obtained 124 medical device registration certificates and filings, enhancing its product line and expanding its presence in the medical field [1] - Chuangli Medical maintains a leading position in the domestic market while actively exploring international markets, with products exported to over 50 countries and regions worldwide [1]

Core Viewpoint - The company is actively innovating in the field of AI medical technology, particularly in surgical robotics for hip and knee procedures, and is committed to continuous product iteration and performance enhancement [1] Summary by Categories Company Innovations - The company has developed and received registration for various surgical robots, including those for hip joint surgery, knee joint surgery, and unicompartmental knee surgery [1] Future Plans - The company aims to integrate innovative technologies to drive product upgrades and breakthroughs in performance [1]

Group 1 - The company is actively investing in cutting-edge medical device technology, focusing on surgical robots for hip and knee procedures [1] - The company has successfully obtained registration certificates for its hip joint surgical robot, knee joint surgical robot, and unicompartmental surgical robot [1] - The company aims to continuously integrate innovative technologies to drive product iteration and performance breakthroughs [1]

Group 1 - The core viewpoint of the article highlights that Chunzhi Medical's stock closed at 23.77 yuan, with a PE ratio of 71.31 times, significantly higher than the industry average of 56.58 times [1][2] - As of March 31, 2025, Chunzhi Medical had 7,167 shareholders, an increase of 501 from the previous count, with an average holding value of 352,800 yuan per shareholder [1] - The company specializes in the research, production, and sales of implantable orthopedic medical devices, including spinal, trauma, joint, sports medicine, and bone repair materials [1] Group 2 - In the latest quarterly report for Q1 2025, Chunzhi Medical reported revenue of 230 million yuan, a year-on-year increase of 3.60%, and a net profit of 58.07 million yuan, up 5.20% year-on-year, with a gross margin of 66.69% [1] - The company was recognized as a champion enterprise in the artificial joint prosthesis manufacturing industry by the Ministry of Industry and Information Technology in 2024 [1] - The average PE ratio for the medical device industry is 56.58 times, with a median of 39.97 times, positioning Chunzhi Medical at the 92nd rank within the industry [1][2]

Core Viewpoint - The stock of Chunli Medical (688236) has shown a recent increase in price and fluctuating capital flows, indicating mixed investor sentiment and potential opportunities for further analysis [1][2]. Group 1: Stock Performance - As of August 15, 2025, Chunli Medical's stock closed at 23.77 yuan, up by 1.89% with a turnover rate of 0.97% and a trading volume of 28,000 hands, resulting in a transaction amount of 65.80 million yuan [1]. - The capital flow data on August 15 shows a net inflow of 388,900 yuan from institutional investors, accounting for 0.59% of the total transaction amount, while retail investors experienced a net outflow of 2.62 million yuan, representing 3.98% of the total [1][2]. Group 2: Recent Capital Flows - Over the past five days, the stock has experienced varying capital flows, with notable net inflows and outflows from different investor categories [2]. - On August 14, the stock saw a significant net outflow of 7.41 million yuan from institutional investors, while retail investors had a net inflow of 3.25 million yuan [2]. Group 3: Financial Metrics and Industry Comparison - Chunli Medical's total market capitalization is 9.117 billion yuan, with a net asset value of 2.879 billion yuan and a net profit of 58.07 million yuan, ranking 42nd, 52nd, and 38th respectively in the medical device industry [3]. - The company reported a gross margin of 66.69% and a net margin of 25.25%, both significantly higher than the industry averages of 51.36% and 10.89% respectively [3]. - Chunli Medical's price-to-earnings ratio is 39.25, which is lower than the industry average of 67.67, indicating a potentially undervalued position in the market [3]. Group 4: Analyst Ratings - In the last 90 days, four institutions have provided ratings for Chunli Medical, with three giving a "buy" rating and one an "accumulate" rating, suggesting a generally positive outlook among analysts [4].

Core Viewpoint - Spring Medical, a leading domestic orthopedic medical device manufacturer, focuses on the research, production, and sales of implantable orthopedic medical devices, including dental metal and invisible orthodontics, and is currently in the design and inspection phase for a customized porous tantalum dental implant product [2][3]. Company Overview - Spring Medical is located in Tongzhou District, Beijing, and was established on February 12, 1998, with its listing date on December 30, 2021. The company specializes in implantable orthopedic medical devices, with main products including joint prosthetics and spinal implants [7][8]. - The company's primary products cover hip, knee, shoulder, and elbow joints, as well as a full range of spinal internal fixation systems [5][8]. Financial Performance - For the period from January to March 2025, Spring Medical achieved operating revenue of 230 million yuan, representing a year-on-year growth of 3.60%, and a net profit attributable to shareholders of 58.07 million yuan, up 5.20% year-on-year [8][9]. - Since its A-share listing, Spring Medical has distributed a total of 359 million yuan in dividends, with 309 million yuan distributed over the past three years [9]. Market Position and Recognition - The company has been recognized as a "specialized, refined, distinctive, and innovative" small giant enterprise, which is the highest honor for small and medium-sized enterprises in China, indicating strong innovation capabilities and high market share [3]. - Spring Medical's products are exported to various regions, including Asia, South America, Africa, Oceania, and Europe, with its main business revenue composition being 99.92% from medical device products [8]. Technical Analysis - The average trading cost of the stock is 19.38 yuan, with recent signs of accumulation, although the accumulation strength is not strong. The current stock price is between resistance at 25.91 yuan and support at 22.60 yuan, suggesting potential for range trading [6].

作者：智投君 本文源自：金融界 8月14日，沪深两融数据显示，春立医疗获融资买入额0.10亿元，居两市第1424位，当日融资偿还额0.10 亿元，净买入81.50万元。 最近三个交易日，12日-14日，春立医疗分别获融资买入0.11亿元、0.08亿元、0.10亿元。 融券方面，当日融券卖出0.00万股，净卖出0.00万股。 ...